Company intelligence / Profile preview

SiNON Nano Sciences

Columbia, South Carolina, United Statessinontx.com ↗
Ownership
Private
Development stage
Other
01

Overview

SiNON Nano Sciences has developed a patented carbon nanoparticle-based drug delivery platform that enables targeted, controlled release of therapeutics across the blood-brain barrier. The company’s preclinical data suggest improved bioavailability and reduced toxicity for both small molecules and biologics in neurological disease models. As of mid 2025, the company is seed-stage and focused on advancing R&D to determine its positioning as a platform or asset company.

Therapeutic areas
NeurologyOncology
Modalities
NanoparticleSmall molecule (as payload)Biologic (as payload)DNA (as payload)
Industry
Biotech
02

Drug pipeline

6 assets

CNP-TPT

Preclinical

5 more assets in the full pipeline.

Beyond the preview

Go deeper on SiNON Nano Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SiNON Nano Sciences.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call